Next Article in Journal
In Vivo Production of HN Protein Increases the Protection Rates of a Minicircle DNA Vaccine against Genotype VII Newcastle Disease Virus
Previous Article in Journal
Influenza A Virus Hemagglutinin Trimer, Head and Stem Proteins Identify and Quantify Different Hemagglutinin-Specific B Cell Subsets in Humans
Previous Article in Special Issue
Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2
Editorial

Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation

Department of Bioengineering, McGill University, Montreal, QC H3A 0E9, Canada
Vaccines 2021, 9(7), 722; https://doi.org/10.3390/vaccines9070722
Received: 25 June 2021 / Accepted: 27 June 2021 / Published: 2 July 2021
(This article belongs to the Special Issue Vectored Vaccines)
Note: In lieu of an abstract, this is an excerpt from the first page.

In 2019, an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease (COVID-19), caused an ongoing public health crisis [...] View Full-Text
MDPI and ACS Style

Kamen, A.A. Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation. Vaccines 2021, 9, 722. https://doi.org/10.3390/vaccines9070722

AMA Style

Kamen AA. Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation. Vaccines. 2021; 9(7):722. https://doi.org/10.3390/vaccines9070722

Chicago/Turabian Style

Kamen, Amine A. 2021. "Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation" Vaccines 9, no. 7: 722. https://doi.org/10.3390/vaccines9070722

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop